Aaron Ellenbogen is a Neurology physician affiliated with Quest Research Institute. OpenAlex indexes 84 publications with 4,712 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
28595 Orchard Lake Rd
Suite 200
Farmington Hills, MI 483342977
Telephone
248-553-0010Registry record last updated 27 Feb 2018.
Clinical trials
- A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
Sponsor: Orient Pharma Co., Ltd.
- Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
Sponsor: Jazz Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year2025105 payments$106,008openpaymentsdata.cms.gov ↗
- MDD US Operations, LLCProgram year202598 payments$102,677openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year202526 payments$38,228openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
93.2%Neuromuscular Blocker93%Onabotulinumtoxina84%Abobotulinumtoxina16%Part B, office-administered≥77 patientsgamma-Aminobutyric Acid-ergic Agonist0.1%Baclofen100%Part D≥29 patients+ 2 more classes in this area
Nervous system
6.4%Aromatic Amino Acid Decarboxylation Inhibitor2%Carbidopa-Levodopa78%Rytary12%Carbidopa-Levodopa Er8%Carbidopa-Levodopa-Entacapone1%Crexont1%Part D<11 patientsBenzodiazepine0.5%Clonazepam65%Lorazepam14%Diazepam12%Alprazolam9%Part D<11 patients+ 32 more classes in this area
Cardiovascular
0.2%Beta blocker0.2%Propranolol Hcl Er68%Propranolol Hcl32%Part D≥26 patientsalpha-Adrenergic Agonist0%Midodrine Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”